Navigation Links
MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Date:8/6/2009

ties in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate and future cash usage. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including risks related to the failure to achieve favorable clinical outcomes and to have the company's LEVADEX(TM) product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and its Quarterly
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 The report "Industrial ... Pollutant Control System (FGD, DeNOx, Particulate Control, Mercury ... Steel, Chemical & Others) - Global Trends & ... industrial flue gas treatment systems & services market ... size in terms of value. The industrial flue ...
(Date:8/21/2014)... Revista, a one-stop source for ... data, is “on a roll.” Today, the Annapolis-based ... the Southeast, Mid-Atlantic and Midwest areas of the ... widely available, comprehensive medical property database tracking these ... properties, including existing and recently added, is 34,549. ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, 2014 ... dropped nearly 12 percent in the last decade, a new ... of teens using indoor tanning beds barely decreased. Both indoor ... skin cancers, including deadly melanomas, the researchers noted. "Unfortunately, ... who reported wearing sunscreen, from 67.7 percent in 2001 to ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... 2014 When children go back to school, ... cause them to become sick and risk missing school. It ... help them fight these germs to ensure a successful school ... just that with its XFactor program. , The XFactor program ... multi-vitamins. Children ages 4 and up can receive 30-day supplies ...
Breaking Medicine News(10 mins):Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:MedX Pharmacy Helps with Back to School Preparation 2
... Calif. - A single dose of antibiotics can significantly ... vaginal tissues during many births, according to researchers at ... School of Medicine and Santa Clara Valley Medical Center. ... simple treatment can prevent many of the short- and ...
... Mylan Inc. (NYSE: MYL ),today announced that ... U.S. Food and Drug Administration (FDA) for its,Abbreviated New ... 10,mg., Zaleplon Capsules are the generic version of ... $88 million for,the 12 months ending March 31, 2008, ...
... handful of measures are,effective, NEWTOWN, Conn., June ... and policy makers about the importance of choosing,the ... measurement,efforts, Bridges to Excellence(TM) (BTE) conducted a review ... physicians meet certain ambulatory,care quality measures. The study, ...
... Company donates $100,000 to American Red Cross, INDIANAPOLIS, ... arm of Eli Lilly and Company (NYSE: LLY ... assistance to aid,Indiana tornado and flood victims. More than ... Gov. Mitch Daniels as a result of deadly,tornadoes and ...
... Va., June 9 The National,Community Pharmacists ... Pharmacists (IACP) are collaborating to increase the,legislative ... in compounding.,IACP has established a satellite office ... Director of Public Affairs, Sarah R. Dodge. ...
... N.J., June 9 Wyeth (NYSE: WYE ... Goldman Sachs Twenty-Ninth,Annual Global Healthcare Conference on June ... Wyeth will be Bernard Poussot, President and Chief,Executive ... live for investors at, http://www.wyeth.com and available ...
Cached Medicine News:Health News:Antibiotics can prevent wound complications of childbirth, Stanford/Packard study finds 2Health News:Bridges to Excellence Study Assesses Clinical and Financial Impact of Physician Quality Measures 2Health News:Lilly to Provide Aid to Indiana Tornado and Flood Victims 2Health News:Pharmacist Associations Partner to Increase the Voice of Pharmacy 2
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... 21, 2014 CVS Caremark Corporation (NYSE: ... Yields and consideration payable in connection with its previously announced ... 2014 for (1) any and all of its 6.250% Senior ... up to a maximum amount of its 6.125% Senior Notes ... Notes due 2017 (collectively, the "Maximum Tender Offer Notes" and ...
(Date:8/21/2014)... 21, 2014 Professional Compounding Centers of ... by awarding the three best scientific presentations at ... conference . The Formulating Better Medicines for ... Athens, Greece , includes dozens ... professionals, from which three winners will be selected ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... THE WOODLANDS, Texas, Aug. 9, 2011 ... ), a biopharmaceutical company focused on discovering breakthrough ... data from its recently completed Phase 2 study ... etiprate. Carcinoid syndrome is a chronic condition caused ...
... SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 9, 2011 ... and Eisai Inc. announced today results from ... mammary tumor diagnoses from a two-year rat carcinogenicity study ... the lorcaserin Complete Response Letter (CRL), which questioned the ...
Cached Medicine Technology:Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 2Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 3Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 4Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 5Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 2Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 3Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 4Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 5Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 6
... plate acc. to Matzen is used for ... (HWS) with the exception of C0-C2. The ... fusion length until the bone transplant has ... the vertebral bodies, if possible along the ...
... The SC-Acufix anterior cervical plate system ... a patented, integrated swivel, which provides for ... and prevents bone screw disengagement or backout. ... a secondary locking screw. Simply implant your ...
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
... consisting of one part only, is made of ... compressed Polyamide may be rotated and moved as ... sizes and shapes, as well. Moreover they secure ... in caudal direction, which is one of the ...
Medicine Products: